As part of the agreement, Aker BioMarine will license and supply Lysoveta to Trofi, who will invest in clinical trials with the aim to develop and commercialize certain medical foods within the fields.
Aker BioMarine (Oslo, Norway) has signed the first commercial agreement for Lysoveta with Trofi Nutritionals (Northbrook, IL) to develop and commercialize medical food products that target male infertility, gestational diabetes and Alzheimer’s disease, as well as pre-natal supplements. Lysoveta features essential nutrients such as choline, EPA, and DHA in the form of Lysophosphatidylcholine (LPC), which plays an important role in the development and function of the brain.
“These diseases have a severe impact on the lives for a large proportion of the population globally. The collaboration with Trofi is an important milestone in commercializing Lysoveta and will continue to build the body of scientific evidence for Lysoveta’s beneficial effects across life stages,” said Matts Johansen, CEO of Aker BioMarine, in a press release.
"The latest science demonstrates that impairment of the MFSD2a transporter in certain diseases can result in DHA deficiency. Therefore, we believe that utilizing Lysoveta as a clinically validated medical food will be well accepted by the physician community" said Trofi co-founder Michael Davidson, MD. Davidson is a Clinical Professor of Medicine and Director of the Lipid Clinic at the University of Illinois.
“The Trofi Lysoveta based nutritional solutions will have the potential to improve the quality of life for millions of people,” added Barbara McCartney CEO, Trofi Nutritionals.
As part of the agreement, Aker BioMarine will license, with associated royalties, relevant intellectual property rights, and supply Lysoveta to Trofi, who will invest in clinical trials with the aim to develop and commercialize certain medical foods within the fields. Trofi is planning to launch the first medical food and dietary supplement in 2024.